[go: up one dir, main page]

PL2187880T3 - Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej - Google Patents

Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej

Info

Publication number
PL2187880T3
PL2187880T3 PL08830106T PL08830106T PL2187880T3 PL 2187880 T3 PL2187880 T3 PL 2187880T3 PL 08830106 T PL08830106 T PL 08830106T PL 08830106 T PL08830106 T PL 08830106T PL 2187880 T3 PL2187880 T3 PL 2187880T3
Authority
PL
Poland
Prior art keywords
compositions
methods
macular degeneration
treating macular
treating
Prior art date
Application number
PL08830106T
Other languages
English (en)
Inventor
Ilyas Washington
Original Assignee
Univ Columbia
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=40452355&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2187880(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Univ Columbia filed Critical Univ Columbia
Publication of PL2187880T3 publication Critical patent/PL2187880T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A61K31/167—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the nitrogen of a carboxamide group directly attached to the aromatic ring, e.g. lidocaine, paracetamol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0048—Eye, e.g. artificial tears
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Emergency Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Ophthalmology & Optometry (AREA)
  • Food Science & Technology (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
PL08830106T 2007-09-12 2008-09-12 Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej PL2187880T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US99337907P 2007-09-12 2007-09-12
PCT/US2008/010676 WO2009035673A1 (en) 2007-09-12 2008-09-12 Compositions and methods for treating macular degeneration
EP08830106.4A EP2187880B1 (en) 2007-09-12 2008-09-12 Compositions and methods for treating macular degeneration

Publications (1)

Publication Number Publication Date
PL2187880T3 true PL2187880T3 (pl) 2014-05-30

Family

ID=40452355

Family Applications (1)

Application Number Title Priority Date Filing Date
PL08830106T PL2187880T3 (pl) 2007-09-12 2008-09-12 Kompozycje i sposoby do leczenia zwyrodnienia plamki żółtej

Country Status (8)

Country Link
US (4) USRE47045E1 (pl)
EP (2) EP2687208A1 (pl)
JP (2) JP5149388B2 (pl)
DK (1) DK2187880T3 (pl)
ES (1) ES2449150T3 (pl)
PL (1) PL2187880T3 (pl)
PT (1) PT2187880E (pl)
WO (1) WO2009035673A1 (pl)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2327401A3 (en) 2003-03-14 2011-10-19 University of Washington Retinoid Replacements and Opsin Agonists and Methods for the Use Thereof
JP5166026B2 (ja) 2004-06-18 2013-03-21 ユニバーシティ オブ ワシントン 視力障害の治療のためのレチナール誘導体およびその使用方法
USRE47045E1 (en) 2007-09-12 2018-09-18 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating macular degeneration
JP6022746B2 (ja) 2008-02-11 2016-11-09 ユニヴァーシティ オブ ワシントン 加齢関連性網膜機能不全の治療及び予防方法
US20090312438A1 (en) * 2008-06-13 2009-12-17 Bernstein Paul S Compositions and Methods for Attenuating the Formation of A2E in the Retinal Pigment Epithelium
JP5663025B2 (ja) 2009-09-15 2015-02-04 キューエルティー インコーポレイテッド ９−ｃｉｓ−レチニルエステルを脂質ビヒクル中に含む医薬製剤
CA2796991A1 (en) 2010-04-19 2011-10-27 Qlt Inc. Therapeutic regimen and methods for treating or ameliorating visual disorders associated with an endogenous retinoid deficiency
MX370928B (es) 2012-03-01 2020-01-08 Retinagenix LLC El uso de 9-cis-retinil acetato para mejorar la función visual de un sujeto que padece de pérdida de la función visual originada por una deficiencia retinoide endógena de 11-cis retinal.
EP2858648B1 (en) 2012-06-07 2018-08-22 Beth Israel Deaconess Medical Center, Inc. Methods and compositions for the inhibition of pin1
DK3855181T3 (da) 2014-02-13 2025-02-10 Katairo Gmbh Forbindelser til behandling af lipofuscinrelaterede sygdomme
US20170112792A1 (en) * 2014-03-21 2017-04-27 Beth Israel Deaconess Medical Center, Inc. Enhanced atra-related compounds derived from structure-activity relationships and modeling for inhibiting pin1
WO2016011265A2 (en) 2014-07-17 2016-01-21 Beth Israel Deaconess Medical Center, Inc. Biomarkers for pin1-associated disorders
KR102276424B1 (ko) * 2014-10-06 2021-07-12 삼성전자주식회사 로-키나제 저해제를 포함하는 세포의 노화를 감소시키기 위한 조성물 및 그의 용도
US9173915B1 (en) 2014-10-10 2015-11-03 Peter F. Kador Antioxidant eye drops
WO2016145186A1 (en) 2015-03-12 2016-09-15 Beth Israel Deaconess Medical Center, Inc. Enhanced atra-related compounds for the treatment of proliferative diseases, autoimmune diseases, and addiction conditions
WO2018112154A1 (en) * 2016-12-15 2018-06-21 Codiak Biosciences, Inc. Methods of measuring exosomes using intrinsic fluorescence
CN118121573B (zh) * 2022-12-01 2025-08-05 复旦大学 一种氘代维生素a及其衍生物的用途
WO2024263751A2 (en) * 2023-06-20 2024-12-26 The Trustees Of Columbia University In The City Of New York Novel co-drug, co-administration, and sequential administration of selective ttr ligand and c20-d3-retinol for elimination of mechanism-based ocular adverse effects in treating macular degeneration and ttr amyloidosis
WO2024263782A2 (en) * 2023-06-20 2024-12-26 The Trustees Of Columbia University In The City Of New York Novel co-drug, co-administration, and sequential administration of bispecific rbp4/ttr ligand and c20-d3-retinol for elimination of mechanism-based ocular adverse effects in treating macular degeneration and ttr amyloidosis
WO2025147467A1 (en) 2024-01-02 2025-07-10 Alkeus Pharmaceuticals, Inc. 10mg to 35mg of gildeuretinol for use in the treatment of stargardt disease
WO2025147228A1 (en) 2024-01-02 2025-07-10 Alkeus Pharmaceuticals, Inc. Treatment for asymptomatic stargardt disease patients with gildeuretinol acetate
WO2025153898A1 (en) * 2024-01-19 2025-07-24 Gene Company Pty Ltd Retinoid compositions and methods of use

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5310764A (en) 1992-05-08 1994-05-10 Steven Baranowitz Treatment of age related macular degeneration with beta-carotene
US5508456A (en) * 1993-07-30 1996-04-16 Ligand Pharmaceuticals Incorporated 9-cis tritium-labeled retinoids and intermediates, methods for their synthesis and methods for their use in discovering retinoid X receptor ligands
US5489611A (en) 1995-02-10 1996-02-06 Warner-Lambert Company Method for lowering plasma levels of lipoprotein (a)
US8198334B2 (en) 1997-10-27 2012-06-12 Pathologica Llc Methods for modulating macrophage proliferation in ocular disease using polyamine analogs
US6593104B1 (en) 1999-02-12 2003-07-15 University Of Iowa Research Foundation Macular degeneration diagnostics and therapeutics
US20030149997A1 (en) 1999-02-19 2003-08-07 Hageman Gregory S. Diagnostics and therapeutics for arterial wall disruptive disorders
JP2003507030A (ja) 1999-08-16 2003-02-25 ヒューマン ジノーム サイエンシーズ， インコーポレイテッド １８個のヒト分泌タンパク質
US20040009907A1 (en) 2001-02-26 2004-01-15 Alsobrook John P. Proteins and nucleic acids encoding same
US20030032078A1 (en) 2001-01-23 2003-02-13 Board Of Regents, The University Of Texas System Methods and compositions for the treatment of macular and retinal degenerations
NZ516873A (en) 2001-02-12 2003-11-28 Warner Lambert Co Compositions containing retinoids and erb inhibitors and their use in inhibiting retinoid skin damage
MXPA03008229A (es) 2001-03-14 2004-11-12 Lilly Co Eli Trienos fluorados y su uso como moduladores rxr.
US6660297B2 (en) 2001-03-23 2003-12-09 Bausch & Lomb Incorporated Nutritional supplement to treat macular degeneration
US20040121407A1 (en) 2002-09-06 2004-06-24 Elixir Pharmaceuticals, Inc. Regulation of the growth hormone/IGF-1 axis
EP1567198A4 (en) 2002-12-02 2006-05-31 Genvec Inc MATERIALS AND METHOD FOR THE TREATMENT OF EYE DISEASES
EP1628631A2 (en) 2003-06-05 2006-03-01 Achkar, Charles C. Methods of treating hyperproliferative cell disorders
US7842722B2 (en) 2003-12-19 2010-11-30 Alcon, Inc. Composition and methods for inhibiting the progression macular degeneration and promoting healthy vision
FR2864871A1 (fr) 2004-01-06 2005-07-08 Thomson Licensing Sa Methode de decouverte d'un reseau domestique et appareil implementant la methode
US7309487B2 (en) 2004-02-09 2007-12-18 George Inana Methods and compositions for detecting and treating retinal diseases
US7566808B2 (en) 2004-02-17 2009-07-28 President And Fellows Of Harvard College Management of ophthalmologic disorders, including macular degeneration
CA2601278C (en) * 2004-03-17 2014-06-10 Lars Michael Larsen Prevention of retinopathy by inhibition of the visual cycle
US20060089411A1 (en) 2004-08-07 2006-04-27 Gierhart Dennis L Treatment of Stargardt's disease and other lipofuscin disorders with combined retinaldehyde inhibitor and zeaxanthin
WO2006033734A2 (en) * 2004-08-18 2006-03-30 Sirion Therapeutics, Inc. Combination compositions comprising 13-cis-retinyl derivatives and uses thereof to treat opthalmic disorders
WO2006047475A2 (en) 2004-10-25 2006-05-04 Sytera, Inc. Detection and analysis of ophthalmically-relevant fluorescent molecules
WO2006052860A2 (en) 2004-11-04 2006-05-18 Sirion Therapeutics, Inc. Modulators of retinol-retinol binding protein (rbp)-transthyretin (ttr) complex formation
SG144145A1 (en) 2004-12-08 2008-07-29 Sirion Therapeutics Inc Methods, assays and compositions for treating retinol-related diseases
US20070014833A1 (en) 2005-03-30 2007-01-18 Sirtris Pharmaceuticals, Inc. Treatment of eye disorders with sirtuin modulators
US20060292099A1 (en) 2005-05-25 2006-12-28 Michael Milburn Treatment of eye disorders with sirtuin modulators
BRPI0610308A8 (pt) 2005-05-26 2017-04-25 Neuron Systems Inc Composições e métodos para o tratamento de doença retinal
UA81382C2 (en) 2005-07-11 2007-12-25 Composition for treating retinol-related diseases by modulation of retinol binding
WO2007037188A1 (ja) * 2005-09-27 2007-04-05 Sapporo Medical University 血管透過性亢進に起因する眼疾患の予防及び治療のための医薬
USRE47045E1 (en) 2007-09-12 2018-09-18 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating macular degeneration
US8263601B2 (en) 2009-02-27 2012-09-11 Concert Pharmaceuticals, Inc. Deuterium substituted xanthine derivatives
EP3090999A1 (en) 2009-06-18 2016-11-09 Concert Pharmaceuticals Inc. Deuterated isoindoline-1, 3-dione derivatives as pde4 and tnf-alpha inhibitors
WO2012057723A1 (en) 2009-10-22 2012-05-03 Proksch, Roger Thermal measurements using multiple frequency atomic force microscopy

Also Published As

Publication number Publication date
EP2187880B1 (en) 2013-12-18
JP5149388B2 (ja) 2013-02-20
DK2187880T3 (da) 2014-03-10
US8877809B2 (en) 2014-11-04
ES2449150T3 (es) 2014-03-18
US20110034554A1 (en) 2011-02-10
EP2187880A1 (en) 2010-05-26
WO2009035673A8 (en) 2009-07-02
EP2687208A1 (en) 2014-01-22
JP5695017B2 (ja) 2015-04-01
USRE47045E1 (en) 2018-09-18
EP2187880A4 (en) 2010-09-08
US9486432B2 (en) 2016-11-08
US20150133549A1 (en) 2015-05-14
PT2187880E (pt) 2014-03-25
US20170128403A1 (en) 2017-05-11
WO2009035673A1 (en) 2009-03-19
JP2010539168A (ja) 2010-12-16
JP2013049711A (ja) 2013-03-14

Similar Documents

Publication Publication Date Title
PT2187880E (pt) Composições e métodos para o tratamento da degenerescência macular
HRP20190214T1 (hr) Pripravci i metode za liječenje purpure
HRP20182135T1 (hr) Pripravci za i postupci liječenja poremećaja povezanih s ige
EP2170309A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF DISEASES
SMT202300433T1 (it) Peptide per l'uso nella prevenzione o nel trattamento della degenerazione maculare
IL202573A0 (en) Methods and compositions for treating allergic diseases
IL202015A0 (en) Methods and compositions for treating skin conditions
IL215932A0 (en) Compositions and methods for treating burns
IL193014A0 (en) Methods and compositions for treating schizophrenia
EP2120561A4 (en) COMPOSITIONS FOR TREATING BIOFILMS, AND METHODS FOR THEIR USE
ZA201101055B (en) Compositions and methods for treating osteoarthritis
IL251169A0 (en) Methods and preparations for stimulating the generation of nerve cells and inhibiting the degeneration of nerve cells through the use of isothiazolopyrimidinones
IL210097A0 (en) Compositions and methods for treating unfluenza
GB2466912B (en) Compositions and methods for treating lysosomal disorders
ZA200900140B (en) Methods and compositions for treating biofilms
PL2252317T3 (pl) Leczenie zwyrodnienia plamki żółtej
HUP0700369D0 (en) Pharmaceutical compositions and method for treating schizofrenia
HRP20130642T1 (en) Methods and compositions for treating cancers
IL173971A0 (en) Compositions and methods for treating and preventing age-related macular degeneration
WO2011097577A9 (en) Compositions and methods for treating or preventing retinal degeneration
ZA201108151B (en) Method and composition for treating macular degeneration
IL213550A0 (en) Method for treating macular degeneration
IL209947A0 (en) Compositions and methods for treating corneal inflammation
GB0625844D0 (en) The treatment of macular degeneration
EP2094279A4 (en) METHOD AND COMPOSITIONS FOR THE TREATMENT OF INFLUENZA